Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Sex (Male/Female) 44/42
Age (years) 59.8 ± 12.8
Duration of diabetes (years) 15.8 ± 9.5
HbA1c (%) 8.5 ± 1.5
Body mass index (kg/m2) 27.3 ± 5.4
Waist circumference (cm) 100.2 ± 11.3
LDL-C (mg/dL) 108.9 ± 33.4
HDL-C (mg/dL) 47.2 ± 13.8
Triglycerides (mg/dL) 136.9 ± 76.3
Hypertension (%) 86
Dyslipidemia (%) 90
Medication for Diabetes  
BG (%) 49
SU (%) 43
αGI (%) 22
TZD (%) 13
DPP4i (%) 17
Glinide (%) 3
Insulin (%) 56
  1. Data are mean ± SD or number of subjects. LDL-C; low-density lipoprotein-cholesterol, HDL-C; high-density lipoprotein-cholesterol, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.